Choroideremia (CHM) MedDRA version: 20.0 Level: LLT Classification code 10008791 Term: Choroideremia System Organ Class: 100000015185
Conditions
Interventions
Product Name: rAAV2.REP1
Pharmaceutical Form: Concentrate for solution for injection
Sponsors
Universitätsklinikum Tübingen, STZ eyetrial am Department für Augenheilkunde
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1.Participant is willing and able to give informed consent for participation in the study. 2.Male aged 18 years or above. 3.Genetically confirmed diagnosis of choroideremia. Patients without a confirmed mutation in the CHM gene, but who have the clinical phenotype typical of choroideremia can only be enrolled if they meet all the following three criteria: (i) family history consistent with X-linked inheritance, (ii) absent REP1 protein on Western blot of a blood sample and, (iii) normal RPE65 gene on sequencing. 4.Active disease visible clinically within the macula region 5.Best-corrected visual acuity equal to or worse than 6/9 (20/32; Decimal 0.63; LogMAR 0.2) but better than or equal to 6/60 (20/200; Decimal 0.1; LogMAR 1.0) in the study eye. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 6 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 6
Exclusion criteria
Exclusion criteria: 1.Female and child participants (under the age of 18) 2.Participants with a history of amblyopia in the study eye 3.Men unwilling to use barrier contraception methods, if relevant 4.Grossly asymmetrical disease or other ocular morbidity which might confound use of the fellow eye as a long-term control 5.Any other significant ocular and non-ocular disease/disorder or retinal surgery which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the results of the study, or the participant’s ability to participate in the study. This would include not taking or having a contraindication to oral prednisolone, such as a history of gastric ulcer or significant side effects. 6.Participants who have participated in another research study involving an investigational product in the past 12 weeks, or having had gene or cellular therapy at any time prior to this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: The proposed clinical trial will assess the effects of the AAV2.REP1 vector in 6 male patients. The primary aim is to assess the anatomical and functional outcomes, as well as the safety of a single subretinal injection of AAV2.REP1 in subjects with genetically confirmed choroideremia for up to 24 months.;Secondary Objective: Secondary study endpoints are, change from baseline in autofluorescence evaluation, microperimetry readings and other anatomic and functional outcomes (all in the study eye compared to control eye). Secondary endpoints also include safety assessments to be conducted throughout the study. The fellow eyes of these patients will be utilised as controls in this study and will receive no study treatment.;Primary end point(s): Anatomical and functional outcomes. The primary outcome measure will be the proportion of patients with a relative change from baseline of =0 in ETDRS letters, when comparing a patient’s treated eye versus the control eye.;Timepoint(s) of evaluation of this end point: D1, D7, M1, M3, M6, M9, M12, M18, M24. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): At each time point, the change from baseline in ETDRS letters will be computed for each eye. The mean change from baseline in ETDRS letters will be presented for both the Treated Eye and the Control Eye groups. At each time point, the change from baseline and the percentage change from baseline in the area of autofluoresence will be computed for each eye and their mean will be presented for both the Treated Eye and the Control Eye groups. With regards to microperimetry, at each time point, the change from baseline in mean sensitivity will be computed for each eye. The mean change from baseline in mean sensitivity will be presented for both the Treated Eye and the Control Eye groups. ;Timepoint(s) of evaluation of this end point: D1, D7, M1, M3, M6, M9, M12, M18, M24. | — |
Countries
Germany
Contacts
Public ContactHead of Department, Barbara Wilhelm
STZ eyetrial am Department für Augenheilkunde
Outcome results
None listed